CBD During Continued Cannabis Use: An Open-Label Improvement Is Not Proof of Protection

forensic toxicology working group members October 28, 2026 Forensic Toxicology

Regular cannabis users improved on selected psychological and cognitive measures during ten weeks of CBD treatment while continuing cannabis use. Without placebo controls, the study cannot establish that CBD protected them from ongoing THC effects.

The exposure was pragmatic

Twenty frequent users received 200 mg oral CBD daily and were monitored weekly. They were not seeking cannabis treatment and continued their usual cannabis use. Assessments compared baseline with the end of treatment.

The design addressed feasibility in an ordinary community sample, rather than a standardized THC challenge with an independently controlled dose.

The reported changes

The researchers observed reductions in depressive and psychotic-like symptoms and improvements in attentional switching, verbal learning and memory. Some changes correlated with plasma CBD concentrations. Participants also retrospectively described less euphoria when using cannabis.

These are different endpoints. Reduced reported euphoria is not evidence that THC exposure disappeared, that every cognitive function normalized or that a participant was fit to drive after consumption.

Why correlation cannot supply the control

Repeated testing can improve task performance, expectations can affect symptom reporting, and other changes can occur during ten weeks. A plasma correlation adds exposure information but does not replace randomization or a placebo group.

The study’s exploratory analyses and small sample further constrain comparisons between dependent and nondependent users. It cannot establish an effective adjunct treatment for cannabis dependence from a sample not seeking that treatment.

The useful conclusion is preliminary: prolonged CBD administration appeared feasible and was associated with selected changes worth testing under controlled conditions.